Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115334) titled 'An open-label, multicenter Phase I clinical study to evaluate the safety, tolerability and immunogenicity of RGL-232 in patients with advanced malignant solid tumors carrying KRAS mutations' on Dec. 24, 2025.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Zhejiang Cancer Hospital
Condition:
Advanced malignant solid tumor
Intervention:
Dose escalation of monotherapy:Preset three dose levels: low, medium and high. Each treatment cycle was set at 3 weeks (Q3W), with administration on the first day of each cycle. After 9 cycles, the administration was adjusted to every 6 weeks (Q6W)...